Iovance Biotherapeutics, Inc. (IOVA) This fall 2025 Earnings Name February 24, 2026 8:30 AM EST
Firm Contributors
Sara Pellegrino – Senior Vice President of Investor Relations & Company Communications
Frederick Vogt – Interim CEO, President, Basic Counsel, Company Secretary & Director
Corleen Roche – Chief Monetary Officer
Daniel Kirby – Chief Business Officer
Igor Bilinsky – Chief Working Officer
Friedrich Graf Finckenstein – Chief Medical Officer
Brian Gastman – Government Vice President of Medical Affairs
Raj Puri – Chief Regulatory Officer
Marc Theoret – Senior Vice President of Regulatory Technique
Convention Name Contributors
Lin Tsai – Jefferies LLC, Analysis Division
Tyler Van Buren – TD Cowen, Analysis Division
Salim Syed – Mizuho Securities USA LLC, Analysis Division
Reni Benjamin – Residents JMP Securities, LLC, Analysis Division
Nick Quartapella – Robert W. Baird & Co. Integrated, Analysis Division
Xiaochuan Dai – UBS Funding Financial institution, Analysis Division
Etzer Darout – Barclays Financial institution PLC, Analysis Division
Asthika Goonewardene – Truist Securities, Inc., Analysis Division
Presentation
Operator
Good day, and thanks for standing by. Welcome to the Iovance Biotherapeutics Fourth quarter and Full Yr 2025 Monetary Outcomes and Company Updates Convention Name. [Operator Instructions] Please be suggested that at the moment’s convention is being recorded.
I might now like at hand the convention over to your speaker at the moment, Sara Pellegrino, Senior Vice President, Investor Relations and Company Communications at Iovance.
Sara Pellegrino
Senior Vice President of Investor Relations & Company Communications
Thanks, operator. Good morning, and welcome to the Iovance webcast to debate our fourth quarter and full yr 2025 monetary outcomes, enterprise achievements and company updates. This morning, we issued a press launch that’s accessible on our company web site at iovance.com. This convention name will embrace forward-looking statements relating to Iovance’s objectives, enterprise focus, enterprise plans and transactions, income, industrial actions, medical trials and outcomes, regulatory approvals and interactions, plans and methods, analysis and preclinical actions, potential future functions of our know-how, manufacturing capabilities, regulatory suggestions and steerage, payer interactions, licenses and collaboration money place and expense
